Loading clinical trials...
Loading clinical trials...
A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
Conditions
Interventions
Bevasiranib
Locations
23
United States
Acuity Participating Site
Phoenix, Arizona, United States
Retina Centers PC
Tucson, Arizona, United States
Sall Research Medical Center
Artesia, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Florida Eye Microsurgical Institute, Inc.
Boynton Beach, Florida, United States
Retina Specialist
Towson, Maryland, United States
Start Date
July 1, 2005
Primary Completion Date
December 1, 2007
Completion Date
December 1, 2007
Last Updated
August 5, 2008
NCT05913063
NCT07446582
NCT06779773
NCT06990269
NCT06970665
NCT07160179
Lead Sponsor
OPKO Health, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions